Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development, the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. Our pipeline is supported by a strong clinical development team and abundant clinical resources.
To learn more about our pipeline, please contact [email protected].
Candidate |
Target |
Combination |
Indication |
Pre-clinical |
Upcoming Milestone |
Rights |
News/Press Release |
|
Clinical-stage Drug Candidates |
YH003 |
CD40 |
PD-1 | Melanoma | Global MRCT
Phase II |
2021 Q4 Patient Recruitment |
Global | Findings From Anti-CD40 Clinical Trials |
| PD-1 | Pancreatic cancer |
Global MRCT
Phase II |
2021 Q4 Patient Recruitment |
|||||
| Monotherapy |
Solid tumors | China Phase I | 2021 Q3 Patient Recruitment |
|||||
| PD-1+ YH001 |
Solid tumors | Australia
IND |
2021 Q4 Patient Recruitment | |||||
| YH001 |
CTLA-4 |
PD-1 | Non-small-cell lung cancer (NSCLC) |
Global MRCT
Phase II |
2021 Q4 Patient Recruitment |
Global |
Findings From Anti-CTLA-4 mAb Clinical Trials |
|
| PD-1 | Hepatocellular carcinoma (HCC) |
Global MRCT
Phase II
|
2021 Q4 Patient Recruitment |
|||||
| Monotherapy | Solid tumors | China
Phase I |
2022 Q1 Complete Phase I trial |
|||||
| YH002 |
OX40 |
Monotherapy | Solid Tumors | Australia
Phase 1 |
2021 Q4 Complete Phase I trial |
Global | Combination Therapy First Patient Dosing | |
| Monotherapy | Solid Tumors | China/USA
Phase 1 |
Launch based on clinical results in Australia |
|||||
| YH001 | Solid Tumors | China/Australia
Phase I |
2022 First Patient Dosing | |||||
| YH004 |
4-1BB |
PD-1 | Hematological malignancies |
Australia
Phase 1 |
2021 Q4 Patient Recruitment |
Global | ||
| PD-1 | Solid tumors | Australia/China
Phase 1
|
2021 Q4 Patient Recruitment |
|||||
| YH005-ADC | Claudin18.2- ADC |
Solid tumors | Australia
IND -> Phase 1 |
2021 Q3 Receive IND approval |
Remegen | |||
| Preclinical Drug Candidates |
YH008 | PD-1/CD40 (bispecific antibody) |
Solid tumors | CMC | Global | |||
| YH006 | CTLA-4/ OX40 (bispecific antibody) |
Solid Tumors | CMC | Global | ||||
| YH009 | RSV | Prevention/ Treatment for RSV infection |
CMC | Global | ||||
| YH010 | PD-L1/IL-12 | Solid Tumors | Discovery | Global | ||||
| YH011 | PD-L1/ cytokine |
Solid Tumors | Discovery | GeneQuantum Healthcare | ||||
| YH012 | Bispecific antibody ADC |
Solid tumors | Discovery | Global | ||||
| YH013 | Bispecific antibody ADC |
Solid tumors | Discovery | Global |
